Shares of Altria Group Inc. (NYSE: MO) have gained 15% year to date and 12% over the past 12 months. The company reported its first quarter 2022 earnings results last week. There is a mixed sentiment surrounding Altria and here are a few points to keep in mind if you are considering this stock:
Better-than-expected results
In Q1, Altria’s net revenues declined 2.4% year-over-year to $5.9 billion but exceeded expectations. The decrease in the top line was mainly due to the sale of the wine business last October. Reported EPS increased 40.3% to $1.08 while adjusted EPS rose 4.7% to $1.12, beating estimates. The bottom line growth was driven mainly by higher operating companies income.
Smoke-free segment
Altria is seeing healthy performance within its smoke-free portfolio from products such as on! and oral nicotine pouches. Reported shipment volume for on! almost doubled YoY to 18 million cans in Q1. At retail, on!’s share of all tobacco increased by 2.5 percentage points to reach 4.1%.
On its quarterly conference call, Altria said that on!’s share growth was mainly driven by repeat purchases from existing customers and increased tobacco consumer trial. At the category level, oral nicotine pouches reached a total oral tobacco retail share of 19.3 percentage points in Q1.
The category grew 6.1 share points YoY, with 40% of this growth coming from on! The brand is doing well in all regions of the US and it is a highly competitive product in the space. Altria is also working on modified-risk tobacco product applications for on!
In e-vapor, total category volume is estimated to have increased 10% YoY and 4% sequentially due to increased volume in the vape store channel.
Balance sheet and shareholder return
At the end of Q1, Altria had cash and cash equivalents of $5 billion and long-term debt of $25.4 billion. During the quarter, the company paid approx. $1.6 billion in dividends and repurchased approx. 11.3 million shares for $576 million.
Outlook
Altria expects full-year 2022 adjusted EPS to grow 4-7% year-over-year to a range of $4.79-4.93. The company expects adjusted EPS growth to be weighted towards the second half of the year.
Inflation
On its call, Altria discussed the impact of macroeconomic factors on US tobacco consumers. In January, the Omicron variant disrupted the routines and purchasing patterns of consumers leading to short-term decreases in retail trips and overall tobacco volumes. Increased inflation throughout the quarter put pressure on discretionary income levels. The company expects inflation to persist through the remainder of the year.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on